Omeros Corporation (OMER)

NASDAQ • Healthcare

$16.57

-$0.28 (-1.7%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$16.8

Previous Close$16.57

Day Range$16.37 - $16.8

Avg. Volume (3M)1M

Market Cap$1.1B

P/E Ratio8.7

52 Week Range

$6.24$21.24

Next EarningsIn 18 daysNov 12, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$28.5M100%

Gross Profitminus cost of goods$27.7M97%

Operating Incomeminus R&D and overhead$74K0%

Net Incomeminus taxes and the rest$13.2M46%

In plain terms: out of every $100 in revenue, Omeros Corporation keeps $46 as net profit.

Fundamentals & Financials

Revenue (TTM)

$38.4M

Net Income (TTM)

$124.8M

EPS (TTM)

$1.91

ROA (TTM)

43.52%

Current Ratio

1.95

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+21.8%Q3 2025-$0.43

+19.0%Q4 2025-$0.47

+670.9%Q1 2026$3.14

+40.0%Q2 2026-$0.24

+155.9%Q3 2026$0.15

Nov 12

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +155.9%

Revenue came in at about $28.5 million in the second fiscal quarter of 2026, as Omeros Corporation reported results on August 13, 2026, with GAAP net income of roughly $13.2 million, up from a net loss of about $25.4 million a year ago. Gross profit was about $27.7 million, with gross margin at ~97%, leaving the quarter’s results heavily concentrated in gross profit relative to revenue. The company generated operating cash flow of around $4.1 million and repurchased roughly $1.6 million of stock during the period. For the next period, consensus calls for EPS of -$0.05 on revenue of $36.7 million.

Next report — what to expect

Omeros Corporation (OMER) reports earnings on November 12, 2026. Wall Street is looking for consensus EPS of $0.03 on consensus revenue of $37.3 million. Recent results show a consistent pattern, with Omeros beating EPS expectations in 7 of its 8 most recent quarters, making updates on revenue and profitability key items to watch.

View full earnings history

About Omeros Corporation

Omeros Corporation is an OMER-listed Biotechnology company on NASDAQ that develops small-molecule and protein-based therapies. The company focuses on inflammatory conditions, complement-mediated diseases, immune-related cancers, and addiction or compulsion disorders, and it is a drug developer founded in 1994 and based in Seattle, Washington.

Name

Omeros Corporation

CEO

Gregory A. Demopulos

Website

www.omeros.com

Industry

Healthcare

Year Founded

1994

Employees

175

Today's Snapshot

AI-generated

The day ended with OMER 1.7% lower at 16.57, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level.

Trading Volume

Below 10d avg (1.2M)

698.8K

vs S&P 500 Today

Underperforming Market

-1.20%

Updated: October 23, 2026 at 20:25 UTC

Technical Indicators

3 Buy1 Neutral4 Sell

OMER exhibits short-term weakness despite some longer-term support, with several momentum measures tilting bearish. The price is below the 10–50 day averages while the 100/200-day lines sit lower, so recent action is corrective against longer-term levels; MACD and momentum are negative and the ATR shows elevated percentage volatility near 5.2%, underscoring the current pressure. Stochastic and Williams readings are oversold, implying short-term mean-reversion potential, yet volume-based measures and moving-average alignment favor the downside. Technical takeaway: Sell bias driven by short-term weakness.

All signals